Laboratory Co. of America Holdings (NYSE:LH - Get Free Report) EVP Der Vaart Sandra D. Van sold 3,553 shares of the business's stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $216.74, for a total transaction of $770,077.22. Following the sale, the executive vice president now directly owns 7,637 shares of the company's stock, valued at approximately $1,655,243.38. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Laboratory Co. of America Trading Up 0.9 %
Shares of NYSE:LH opened at $218.46 on Friday. The company has a current ratio of 1.17, a quick ratio of 1.02 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $18.37 billion, a PE ratio of 46.78, a P/E/G ratio of 1.65 and a beta of 1.02. Laboratory Co. of America Holdings has a 1 year low of $174.20 and a 1 year high of $234.09. The firm has a fifty day moving average price of $218.91 and a 200 day moving average price of $214.11.
Laboratory Co. of America (NYSE:LH - Get Free Report) last announced its earnings results on Thursday, February 15th. The medical research company reported $3.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.29 by $0.01. Laboratory Co. of America had a return on equity of 13.99% and a net margin of 3.24%. The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.02 billion. During the same quarter in the prior year, the business earned $4.14 earnings per share. The company's revenue was down 17.5% on a year-over-year basis. Analysts expect that Laboratory Co. of America Holdings will post 14.77 EPS for the current fiscal year.
Laboratory Co. of America Announces Dividend
Elon’s New A.I. Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 13th. Stockholders of record on Tuesday, February 27th were paid a $0.72 dividend. The ex-dividend date was Monday, February 26th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.32%. Laboratory Co. of America's payout ratio is presently 61.67%.
Analysts Set New Price Targets
Several equities analysts have recently commented on LH shares. Evercore ISI began coverage on shares of Laboratory Co. of America in a research report on Friday, February 9th. They set an "in-line" rating and a $240.00 price target for the company. TheStreet lowered shares of Laboratory Co. of America from a "b-" rating to a "c+" rating in a research note on Thursday, February 15th. Argus raised Laboratory Co. of America from a "hold" rating to a "buy" rating and set a $250.00 price objective for the company in a report on Monday, March 25th. Barclays initiated coverage on Laboratory Co. of America in a research note on Wednesday, January 3rd. They set an "equal weight" rating and a $222.00 target price on the stock. Finally, SVB Leerink assumed coverage on Laboratory Co. of America in a research note on Monday, February 26th. They issued an "outperform" rating and a $260.00 price target for the company. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $243.50.
View Our Latest Analysis on Laboratory Co. of America
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. Lazard Asset Management LLC raised its holdings in Laboratory Co. of America by 532.2% in the 4th quarter. Lazard Asset Management LLC now owns 1,530,675 shares of the medical research company's stock valued at $360,441,000 after acquiring an additional 1,288,574 shares in the last quarter. Norges Bank acquired a new stake in shares of Laboratory Co. of America in the 4th quarter valued at $291,045,000. Morgan Stanley grew its holdings in shares of Laboratory Co. of America by 102.6% in the 3rd quarter. Morgan Stanley now owns 2,219,291 shares of the medical research company's stock worth $446,189,000 after purchasing an additional 1,123,755 shares during the last quarter. Diamond Hill Capital Management Inc. increased its position in shares of Laboratory Co. of America by 644.2% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 1,280,884 shares of the medical research company's stock worth $257,522,000 after purchasing an additional 1,108,776 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in Laboratory Co. of America by 3,836.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 806,975 shares of the medical research company's stock valued at $162,243,000 after buying an additional 786,477 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors and hedge funds.
Laboratory Co. of America Company Profile
(
Get Free Report)
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
